Home   Contact Palatin   Site Map  
 

Overview

Palatin Technologies (AMEX:PTN) is a biopharmaceutical company dedicated to the development of proprietary peptide, peptide mimetic and small molecule agonist compounds with a focus on therapeutics that modulate melanocortin and natriuretic peptide receptor systems.  The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia and reperfusion injury, hemorrhagic shock and inflammation-related diseases.  The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases.

Palatin has collaborations with industry leaders AstraZeneca (NYSE:AZN) and the Mallinckrodt division of Covidien (NYSE:COV).

Product Portfolio

  • PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of heart failure, including congestive heart failure.
  • Bremelanotide, a peptide melanocortin receptor agonist, for prevention of organ damage secondary to cardiac surgery and related indications.
  • PL-3994, a peptidomimetic natriuretic peptide receptor A agonist, for treatment of difficult-to-control hypertension, including dialysis patients with hypertension.
  • PL-6983, a peptide melanocortin-4 receptor agonist, for treatment of female sexual dysfunction.
  • Ongoing research collaboration and global license with AstraZeneca AB on melanocortin receptor-based compounds for treating obesity and related metabolic syndrome.
  • NeutroSpec, a radiolabeled monoclonal antibody product for imaging and diagnosing infection, is the subject of a strategic collaboration agreement with the Mallinckrodt division of Covidien.  All ongoing clinical trials and regulatory approvals of NeutroSpec have been suspended while the Company and Mallinckrodt evaluate future development and marketing activities involving NeutroSpec.